VANCOUVER, July 20 /CNW/ - Protox(TM) Therapeutics Inc. (TSX-V:PRX) today announced that it has acquired a Phase II clinical stage program for the treatment of cancer from Neurocrine Biosciences Inc. and the United States Public Health Service (PHS). The targeted therapeutic toxin PRX321, formerly known as NBI-3001, has received both Fast Track Designation and Orphan Drug Status from the U.S. Food and Drug Administration (FDA) for primary brain tumors. Fast Track Designation enables expedited review by the FDA of products that are in clinical development and Orphan Drug Status provides a number of benefits including seven years of market exclusivity.
